Sidley Represents Rigel Pharmaceuticals in US$320 Million License Agreement With Arvinas and Pfizer

Sidley represented Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) in its exclusive global license agreement with Arvinas, Inc. and Pfizer, Inc., subject to regulatory clearance, to develop, manufacture, and commercialize VEPPANU™ (vepdegestrant), the first FDA-approved oral PROTAC therapy. Arvinas and Pfizer will receive an upfront US$70 million and an additional US$15 million upon the successful completion of certain transition activities, and are eligible for up to US$320 million in future potential regulatory and commercial milestones. Vepdegestrant demonstrated positive Phase 3 clinical results in patients with advanced or metastatic breast cancer.

For more information about the transaction, please read the press release here.

The Sidley team was led by Adriana Tibbitts (Technology and Life Sciences Transactions) and included Cassidy Pomeroy-Carter and Karena Kong (Technology and Life Sciences Transactions); Scott Williams and Carlton Fleming (Corporate Governance); Vadim Brusser, Mary Marks, Murray Reeve, and Arthur Clover (Antitrust and Competition); Leslie Shubert (White Collar: Government Litigation and Investigations); and Chelsey Miao (Commercial Litigation and Disputes).